Pages that link to "Q31108636"
Jump to navigation
Jump to search
The following pages link to Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma (Q31108636):
Displaying 10 items.
- Sorafenib in combination with low-dose-homoharringtonine as a salvage therapy in primary refractory FLT3-ITD-positive AML: a case report and review of literature (Q26765296) (← links)
- Hepatotoxicity of targeted therapy for cancer. (Q30250288) (← links)
- Sorafenib-Induced Grade Four Hepatotoxicity in a Patient with Recurrent Gastrointestinal Stromal Tumor (GIST): A Case Report and Review of Literature (Q35618166) (← links)
- Hepatotoxicity of molecular targeted therapy (Q35648962) (← links)
- Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives (Q38101884) (← links)
- Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats (Q38714036) (← links)
- Drug-induced hepatotoxicity in cancer patients - implication for treatment (Q38845891) (← links)
- Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. (Q46274363) (← links)
- Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? (Q47397616) (← links)
- Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity (Q93052483) (← links)